Prevention of sudden cardiac death in childhood-onset hypertrophic cardiomyopathy

Elliott, 2014, 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284 Arola, 1997, Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland, Am J Epidemiol, 146, 385, 10.1093/oxfordjournals.aje.a009291 Nugent, 2003, The epidemiology of childhood cardiomyopathy in Australia, N Engl J Med, 348, 1639, 10.1056/NEJMoa021737 Lipshultz, 2003, The incidence of pediatric cardiomyopathy in two regions of the United States, N Engl J Med, 348, 1647, 10.1056/NEJMoa021715 Norrish, 2019, Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom, Eur Heart J, 40, 986, 10.1093/eurheartj/ehy798 Kaski, 2009, Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy, Circ Cardiovasc Genet, 2, 436, 10.1161/CIRCGENETICS.108.821314 Nugent, 2005, Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study, Circulation, 112, 1332, 10.1161/CIRCULATIONAHA.104.530303 Colan, 2007, Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry, Circulation, 115, 773, 10.1161/CIRCULATIONAHA.106.621185 Morita, 2008, Shared genetic causes of cardiac hypertrophy in children and adults, N Engl J Med, 358, 1899, 10.1056/NEJMoa075463 Marston, 2021, Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy, Eur Heart J, 42, 1988, 10.1093/eurheartj/ehab148 Varnava, 2001, Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy, Am J Cardiol, 88, 275, 10.1016/S0002-9149(01)01640-X Wang, 2018, Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes, J Mol Cell Cardiol, 114, 320, 10.1016/j.yjmcc.2017.12.002 Saumarez, 1995, Primary ventricular fibrillation is associated with increased paced right ventricular electrogram fractionation, Circulation, 92, 2565, 10.1161/01.CIR.92.9.2565 McKenna, 1988, Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy, J Am Coll Cardiol, 11, 147, 10.1016/0735-1097(88)90181-7 McKenna, 1984, Hypertrophic cardiomyopathy: an important cause of sudden death, Arch Dis Child, 59, 971, 10.1136/adc.59.10.971 Norrish, 2019, Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM risk-kids), JAMA Cardiol, 4, 918, 10.1001/jamacardio.2019.2861 Miron, 2020, A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy, Circulation, 143, 217, 10.1161/CIRCULATIONAHA.120.047235 O’Mahony, 2018, International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM), Circulation, 137, 1015, 10.1161/CIRCULATIONAHA.117.030437 O’Mahony, 2014, A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD), Eur Heart J, 35, 2010, 10.1093/eurheartj/eht439 Ostman-Smith, 1999, A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment, J Am Coll Cardiol, 34, 1813, 10.1016/S0735-1097(99)00421-0 Kaski, 2007, Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy, Heart, 93, 372, 10.1136/hrt.2006.094730 Maron, 2013, Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 1527, 10.1016/j.jacc.2013.01.037 Norrish, 2020, Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study, Europace, 23, 400, 10.1093/europace/euaa307 Kamp, 2013, Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study, Pediatr Cardiol, 34, 1620, 10.1007/s00246-013-0676-6 Dechert, 2016, Implantable cardioverter defibrillator outcomes in pediatric and congenital heart disease: time to system revision, Pacing Clin Electrophysiol, 39, 703, 10.1111/pace.12878 O’Mahony, 2012, The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy, Heart, 98, 116, 10.1136/hrt.2010.217182 Ommen, 2020, 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, Circulation, 142 Norrish, 2017, Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: a systematic review and meta-analysis, Eur J Prev Cardiol, 24, 1220, 10.1177/2047487317702519 Norrish, 2019, A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy, Europace, 21, 1559, 10.1093/europace/euz118 O’Mahony, 2018, An international external validation study of the 2014 European Society of Cardiology Guideline on sudden cardiac death prevention in hypertrophic cardiomyopathy (evidence from HCM), Circulation, 137, 1015, 10.1161/CIRCULATIONAHA.117.030437 Ostman-Smith, 2008, Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy, Eur Heart J, 29, 1160, 10.1093/eurheartj/ehn122 Weng, 2016, Prognostic value of LGE-CMR in HCM: a meta-analysis, JACC Cardiovasc Imaging, 9, 1392, 10.1016/j.jcmg.2016.02.031 Axelsson Raja, 2018, Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy, Circulation, 138, 782, 10.1161/CIRCULATIONAHA.117.032966 Windram, 2015, Distribution of hypertrophy and late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy, Congenit Heart Dis, 10, E258, 10.1111/chd.12286 Petryka-Mazurkiewicz, 2020, LGE for risk stratification in primary prevention in children with HCM, JACC Cardiovasc Imaging, 13, 2684, 10.1016/j.jcmg.2020.06.009 Norrish, 2021, The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy, Eur J Prev Cardiol Harper, 2021, Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity, Nat Genet, 53, 135, 10.1038/s41588-020-00764-0 Calcagni, 2017, Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results, Int J Cardiol, 245, 92, 10.1016/j.ijcard.2017.07.068 Maskatia, 2012, Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy, Pediatr Cardiol, 33, 141, 10.1007/s00246-011-0106-6 Ziolkowska, 2016, Predictors of long-term outcome in children with hypertrophic cardiomyopathy, Pediatr Cardiol, 37, 448, 10.1007/s00246-015-1298-y Balaji, 2019, Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study, Heart Rhythm, 16, 1462, 10.1016/j.hrthm.2019.04.040 Alexander, 2018, Long-term outcomes of hypertrophic cardiomyopathy diagnosed during childhood: results from a National Population-Based Study, Circulation, 138, 29, 10.1161/CIRCULATIONAHA.117.028895 Ostman-Smith, 2005, Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly, Cardiol Young, 15, 632, 10.1017/S1047951105001824 Ostman-Smith, 2017, Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score, Open Heart, 4, 10.1136/openhrt-2017-000658 Smith, 2014, Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy, Am J Cardiol, 113, 1234, 10.1016/j.amjcard.2013.12.034 Mathew, 2018, Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy, Clin Genet, 93, 310, 10.1111/cge.13157 Maurizi, 2018, Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events, JAMA Cardiol, 3, 520, 10.1001/jamacardio.2018.0789